Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
NACRES:
SB.32
UNSPSC Code:
41121813
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
feature
Disposable plastic, Wavelength range: 230 to 900 nm, semi-micro
manufacturer/tradename
BRAND 759150
chamber volume
1.5-3 mL
window W × H
4.5 mm × 2.3 mm
General description
Ideally suited for concentration determinations through spectroscopy assays in water analysis, chemistry, and ife science applications. CERTIFIED LIFE SCIENCE QUALITY: Virgin raw materials, Manufactured under controlled room conditions, Intensive in-process controls, Visual inspections, Batch management, Final product inspection, Proven functionality.
Application
BRAND® UV cuvettes have been used in antigen adsorption and total protein content spectroscopy assays.
Features and Benefits
- Compatible with acid, alkaline solutions, and the majority of polar solvents
- Low price with significantly lower risk of contamination as compared to other quartz glass cuvettes
- Standard 10 mm light path.
Other Notes
BR759150 (India)
Legal Information
BRAND is a registered trademark of BRAND GMBH + CO KG
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Sven Jirschitzka et al.
Archiv der Pharmazie, 356(6), e2300072-e2300072 (2023-03-29)
Pertuzumab (Perjeta®) is a monoclonal antibody approved for the treatment of HER2-positive breast cancer. Before treatment, the concentrate must be diluted to obtain the ready-to-use infusion solution. Data on the storage stabilities of these preparations are lacking but important for all
Kyle Lakatos et al.
Human vaccines & immunotherapeutics, 16(8), 1957-1968 (2020-01-30)
More effective rotavirus vaccines are essential for preventing extensive diarrheal morbidity and mortality in children under five years of age in low-resource regions. Nonreplicating rotavirus vaccines (NRRV) administered parenterally provide an alternate vaccination method to the current licensed oral vaccine.